Table 1. Clinical outcomes at 6 months for RTX treated patients according to RF and ACPA status
| RF (+) | RF (–) | p-value | ACPA (+) | ACPA (–) | p-value | |
|---|---|---|---|---|---|---|
| Baseline DAS28 | 5.85±1.36 | 5.63±1.34 | 0.001* | 5.8±1.35 | 5.68±1.32 | NS |
| DeltaDAS28 6m | 1.94±1.5 | 1.65±1.34 | 0.005 | 1.93±1.51 | 1.40±1.47 | <0.0001 |
| EULAR Good/Moderate/No 6m | 21.5/62/16.5% | 17.4/63.4/19.2% | 0.06 | 23.9/58.7/17.4% | 14.9/62.9/22.2% | 0.009 |
| Remission 6m | 13.8% | 11.3% | NS | 13.5% | 10.9% | NS |
| DP | DN | p-value | RF and/or ACPA (+) | DN | p-value | |
| Baseline DAS28 | 5.81±1.36 | 5.65±1.36 | NS | 5.84±1.35 | 5.65±1.36 | NS |
| DeltaDAS28 6m | 1.95±1.54 | 1.41±1.51 | 0.007 | 1.93±1.49 | 1.41±1.51 | 0.005 |
| EULAR Good/Moderate/No 6m | 24.7/58.4/16.9% | 13.8/65/21.2% | 0.06 | 21.4/61.9/16.7% | 13.8/65/21.2% | 0.038 |
| Remission 6m | 13.9% | 12.5% | NS | 13.7% | 12.5% | NS |
*Corrected for baseline DAS28.